Abbott/Biocompatibles
This article was originally published in The Gray Sheet
Executive Summary
Firms forge multi-year agreement for Abbott to exclusively distribute Biocompatibles' BiodivYsio coated stent products in the U.S. Abbott also gains rights to Biocompatibles' pipeline of other interventional vascular products and an option to license proprietary phosphorylcholine (PC) coating technology for other Abbott vascular devices worldwide. The PC coating is designed to improve performance, reduce restenosis and thrombosis. A U.S. regulatory filing for the stent will be submitted by Biocompatibles by year-end
You may also be interested in...
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.
EU Stakeholders Devise Six-Point Plan To Improve Cross-Border Clinical Trials
Sponsors need guidance on ethics requirements and clarity around national regulations to conduct cross-border clinical trials in the EU, a multi-stakeholder forum says.